Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.42 |
| ▸ | VEGFA | P15692 | 5/20 | 0.42 |
| ▸ | FLT1 | P17948 | 5/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26260139 | 0.89 | EGLN1 (0.42) | EGLN1VEGFAFLT1EGLN3CASP1 | |
| SCHEMBL30452770 | 0.78 | VEGFA (0.49) | EGLN1VEGFAFLT1EGLN3LMNA | |
| SCHEMBL24257835 | 0.78 | VEGFA (0.49) | EGLN1VEGFAFLT1EGLN3LMNA | |
| SCHEMBL24257568 | 0.77 | EGLN1 (0.58) | EGLN1VEGFAFLT1EGLN3CASP1 | |
| SCHEMBL24257625 | 0.76 | ALDH1A1 (0.39) | EGLN1VEGFAFLT1EGLN3LMNA | |
| SCHEMBL23501744 | 0.74 | ALDH1A1 (0.48) | EGLN1VEGFAFLT1EGLN3CASP1 | |
| SCHEMBL24257692 | 0.74 | ALDH1A1 (0.43) | LMNASMN1; SMN2NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL24257605 | 0.73 | EGLN1 (0.56) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL24257741 | 0.72 | SMN1; SMN2 (0.39) | EGLN1VEGFAFLT1EGLN3LMNA | |
| SCHEMBL24257775 | 0.72 | NPC1 (0.37) | EGLN1VEGFAFLT1EGLN3CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885VEGFA 1862/4885FLT1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.